AB Science today provides an update on its masitinib platform

AB Science

Wed, Jan 29, 2025, 11:03 AM 4 min read

New confirmatory study AB23005 simplified for enrolment and targeting best responders for masitinib will be initiated in line with recommendation of FDA and EMA
Design validated by FDA and EMA
Confirmatory study authorized by FDA
Pathway to registration secured with agencies
Discussion with partners facilitated
First study AB10015 generated strong hypothesis on patients normal progressor and prior to any complete loss of function with significant +12 months survival
Long term follow-up shows 53% of patients surviving more than 5 years, with a +36 months benefit over ENCALS prediction
Some patients survived from 10 to 15 years and continue to take treatment

Progressive Forms of Multiple Sclerosis

Mechanism of action targeting microglia reinforced after the success of a BTK inhibitor which also targets microglia
Targeting mast cells adds to the efficacy since mast cells activate microglia and directly acts on myelin degradation
Masitinib Hazard Ratio of EDSS progression compared with BTK inhibitor Hazard Ratio published shows that masitinib is competitive, even if the populations are not comparable and the comparison is indirect
KOLs are very supportive of masitinib program

Alzheimer’s Disease

Targeting the innate immune reaction stands out in addition to main strategy with biologics aimed at reducing beta amyloid or Tau protein plaques
Masitinib is the only drug that generated positive results in moderate Alzheimer’s Disease
Masitinib could be combined with biologics in early and mild Alzheimer’s Disease

More globally

The failure of multiple programs for decades reinforces the value of masitinib approach to target the innate immune reaction through modulation of microglia and mast cells
The unmet medical need in those three indications is immense
The markets are huge with potential sales exceeding billions in each indication
Masitinib IP rights are secured through use patent until 2037 in ALS and up to 2041 in MS and AD, and by orphan drug status in ALS and data protection of 10 years in Europe and 8 years in the USA

Negotiation with banks

AB Science has a debt of 3.7M€ related to PGE (Prêt Garanti par l’Etat) and intends to negotiate a stand-still clause
Current resources should be allocated to R&D program exclusively

About AB Science
Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment.
AB Science has developed a proprietary portfolio of molecules and the Company’s lead compound, masitinib, has already been registered for veterinary medicine and is developed in human medicine in oncology, neurological diseases, inflammatory diseases and viral diseases. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB).

Further information is available on AB Science’s website:
www.ab-science.com.

Forward-looking Statements - AB Science
This press release contains forward-looking statements. These statements are not historical facts. These statements include projections and estimates as well as the assumptions on which they are based, statements based on projects, objectives, intentions and expectations regarding financial results, events, operations, future services, product development and their potential or future performance.

These forward-looking statements can often be identified by the words "expect", "anticipate", "believe", "intend", "estimate" or "plan" as well as other similar terms. While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are difficult to predict and generally beyond the control of AB Science and which may imply that results and actual events significantly differ from those expressed, induced or anticipated in the forward-looking information and statements. These risks and uncertainties include the uncertainties related to product development of the Company which may not be successful or to the marketing authorizations granted by competent authorities or, more generally, any factors that may affect marketing capacity of the products developed by AB Science, as well as those developed or identified in the public documents published by AB Science. AB Science disclaims any obligation or undertaking to update the forward-looking information and statements, subject to the applicable regulations, in particular articles 223-1 et seq. of the AMF General Regulations.

For additional information, please contact:

AB Science
Financial Communication & Media Relations
investors@ab-science.com

Attachment